The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

Phase 3TerminatedNCT00503698

Novo Nordisk A/S712 enrolled

Overview

This trial is conducted in Africa, Asia, Europe, North and South America and Oceania. The aim of the trial is to evaluate the effect of somatropin (human growth hormone) on survival (primary end-point; "time to death" and health related quality of life in adult patients on chronic haemodialysis.

The decision to discontinue the trial is not due to safety concerns. The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

712

Conditions

Chronic Kidney Disease End-Stage Renal Disease

Interventions

somatropinDRUG

20 mcg/kg/day, injected s.c. (under the skin)

placeboDRUG

Placebo injected s.c (under the skin)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Serum albumin as specified in protocol * Malnourished (based on serum albumin value below 40 g/L, assessed centrally) * Stable (for 3 months or more) and adequate haemodialysis treatment three months prior to enrolment as defined by Kt/V of more than 1.2 Exclusion Criteria: * Active malignant disease * Critical illness requiring treatment in an intensive care unit (ICU) * Uncontrolled treated/untreated hypertension * Patients on chronic (more than 3 months) treatment with steroids in doses of more than 10 mg/day prednisolone (or equivalent) * Patients treated with immunosuppressive agents * Known Growth Hormone Deficiency * Patients suffering from any clinically significant disease history in the opinion of the investigator * Severe illness as defined in the protocol (as judged by the investigator)

Locations (381)

Outcomes

Primary Outcomes

Mortality - Time to All-cause Death

Time to all-cause death. Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants dead estimated using Kaplan-Meier. Summary data illustrates mortality until 52 weeks, because very few subjects had trial time longer than 52 weeks. Due to early trial termination, median trial time was 17.4 weeks.

Time frame: week 0, trial termination

Secondary Outcomes

Morbidity - Time From Randomisation to Next Cardiovascular Event (Defined as Composite of All-cause Mortality, Non-fatal Myocardial Infarction, Stroke, Cardiac Insufficiency and Other Thrombo-embolic Event)

Morbidity - time from week 0 to next cardiovascular event (composite of all-cause mortality and cardiovascular events defined as adjudicated medical event of special interest and categorised as myocardial infarctions, cardiac insufficiencies, strokes or other thrombo-embolic events). Statistical analysis is based on all available information from week 0 to trial termination. Summary data illustrates percentage (%) participants with events estimated using Kaplan-Meier. Summary data illustrates morbidity until 52 weeks, because very few subjects had trial time longer than 52 weeks.

Time frame: week 0, trial termination

Morbidity - Number of Hospitalisations, in Addition to Normal Dialysis Procedures

The number of times that the patient was hospitalised in addition to hospitalisation for normal dialysis procedures measured from week 0 (randomisation) to the time the trial was terminated.

Time frame: week 0, trial termination

Mortality - Two-year Mortality Rate

Time frame: week 0, trial termination

Health Related Quality of Life Assessments

Summary from activity of daily living from the Rotterdam Symptom Checklist (RSCL) measuring activity from 1 (active) to 5 (inactive). The Edmonton Symptom Assessment System (ESAS), subjects assess their health in the last 24 hours on a scale from 1 (good health) to 3 (feeling poorly). The EQ-5D is a measure of subjects' health outcome from 0 (death) to 1 (full health). SF-36 (Short Form (36)) covering mental and physicial health is provided in a scale from 0-100 with higher scores indicating greater satisfaction.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.